ADC Candidate Utilizing Rigachem Bio Technology Receives FDA Orphan Drug Designation
Securing FDA Support for Osteosarcoma Treatment Development
First-in-Human Phase 1 Trial Scheduled for Second Half of the Year
Rigachem Bio announced on June 4 that its partner, SOTIO Biotech, has received Orphan Drug Designation (ODD) from the U.S. Food and Drug Administration (FDA) for the antibody-drug conjugate (ADC) candidate 'SOT106' for the treatment of osteosarcoma.
SOT106 is a candidate in which SOTIO's LRRC15-targeted antibody is combined with Rigachem Bio's ADC platform technology, 'Conjuall.'
LRRC15 is a protein known to be expressed at low levels in normal tissue but highly expressed in various sarcoma cancer cells and the tumor microenvironment. According to the companies, preclinical studies have confirmed the anti-cancer efficacy and tolerability of SOT106 in models of soft tissue sarcoma and osteosarcoma. SOTIO plans to begin the first-in-human clinical trial for SOT106 in the second half of this year.
Osteosarcoma is the most common primary bone cancer in children and adolescents, with poor prognosis for patients with recurrence or metastasis and limited treatment options. Receiving FDA Orphan Drug Designation provides benefits such as up to seven years of market exclusivity after approval, reduced regulatory fees, and regulatory support during the development process.
Hot Picks Today
"Two Spend 500,000 Won in a Flash, Yet Wait Two Hours?" ... 'Dreamland' Shunned by Kids and Foreign Tourists
- The Era of Getting 200 Million Won After 30 Years Is Over... A Japanese Bank's "Perpetual Department Head" Who Just Clocked In Cries Out
- Spain Hit by Its Worst Tragedy... Lee Kangin, Moreno and Real Madrid Join Soccer World in Mourning
- They Said, “Make It Your Home for Life” - Then Suddenly Kicked 200 Passengers Off... What Happened to the Around-the-World Cruise?
- "130 Rice Bowls Sold Out in a Day"... 'Unfiltered Face' Adds 8 Million Won to Night Market Sales: China's Bungeunwoo
Radek Spisek, CEO of SOTIO, stated, "Osteosarcoma is an area where there has been little therapeutic innovation for decades. With this designation, we plan to accelerate the clinical development of SOT106."
© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.